(Bloomberg) — Pfizer Inc. won't bring an over-the-counter version of its cholesterol pill Lipitor to the U.S. market, after a trial found that patients couldn't take the drug correctly without a doctor's help.
Pfizer's decision to kill the over-the-counter program ends a years-long effort designed to preserve sales of what was once the New York-based company's — and the world's — top-selling drug. Since losing patent protection in 2011, Lipitor's sales have fallen from more than $10 billion a year to $2.06 billion last year.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
